Association of PD-L1 Expression with Clinicopathologic Characters in Gastric Cancer: A Comprehensive Meta-analysis


Cite item

Full Text

Abstract

Purpose::The expression level of programmed death ligand-1(PD-L1) in patients with gastric cancer is the key to determining the use of immune drugs. The relationship between PD-L1 expression level and clinical characteristics is worth exploring.

Methods::By setting the search terms correlated to PD-L1 and gastric cancer, a nearly comprehensive search was carried out in four major databases, and the deadline for searching was September 1, 2022. The retrieved documents were further screened by strict inclusion and exclusion criteria after removing the duplication. Next, the quality of the included studies was evaluated with the Newcastle-Ottawa Scale (NOS) scale. Finally, the STATA15.1 software was used to process data and draw plots, and the odds ratios (ORs) were adopted to assess the pooled effect size.

Results::A total of 85 works of literature were included in this study through screening strictly, and detailed data were extracted after evaluating the quality of the literature. The process of analysis was conducted in the whole population, Asia-Africa population, European and American population, and Asian population with CPS≥1, amd all found that the expression of PD-L1 in gastric cancer was correlated with age, tumor size, EBV infection, Her-2 expression and microsatellite status. However, the subgroup of the region also found some differences in Asian and Western regions, which was interesting and worth studying further. The included research of this study did not have significant publish bias.

Conclusion::After careful analysis, this study found that age (>60 years), tumor size (>5cm), EBV infection (+), Her-2 expression (+), microsatellite status (MSI), and mismatch repair status (dMMR) were risk factors for positive expression of PD-L1 in gastric cancer.

About the authors

Zhuo Han

Department of General Surgery, Tangdu Hospital, The Air Force Medical University

Email: info@benthamscience.net

Nan Wang

Department of General Surgery, Tangdu Hospital, The Air Force Medical University

Email: info@benthamscience.net

Qing Qiao

Department of General Surgery, Tangdu Hospital, The Air Force Medical University

Email: info@benthamscience.net

Xianli He

Department of General Surgery, Tangdu Hospital, The Air Force Medical University

Email: info@benthamscience.net

Nan Wang

Department of General Surgery, Tangdu Hospital, The Air Force Medical University

Author for correspondence.
Email: info@benthamscience.net

References

  1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2021, 71(3), 209-249. doi: 10.3322/caac.21660 PMID: 33538338
  2. Chen, Y.; Chen, T.; Fang, J.Y. Burden of gastrointestinal cancers in China from 1990 to 2019 and projection through 2029. Cancer Lett., 2023, 560, 216127. doi: 10.1016/j.canlet.2023.216127 PMID: 36933779
  3. Zheng, R.S.; Zhang, S.W.; Sun, K.X.; Chen, R.; Wang, S.M.; Li, L.; Zeng, H.M.; Wei, W.W.; He, J. Cancer statistics in China, 2016. Zhonghua Zhong Liu Za Zhi, 2023, 45(3), 212-220. PMID: 36944542
  4. Fang, X.; Xu, J.; Jin, K.; Qian, J. Combining of immunotherapeutic approaches with chemotherapy for treatment of gastric cancer: Achievements and limitations. Int. Immunopharmacol., 2023, 118, 110062. doi: 10.1016/j.intimp.2023.110062 PMID: 36965367
  5. Yoon, J.; Kim, T.Y.; Oh, D.Y. Recent progress in immunotherapy for gastric cancer. J. Gastric Cancer, 2023, 23(1), 207-223. doi: 10.5230/jgc.2023.23.e10 PMID: 36751000
  6. Janjigian, Y.Y.; Shitara, K.; Moehler, M.; Garrido, M.; Salman, P.; Wyrwicz, L.; Yamaguchi, K.; Skoczylas, T.; Bragagnoli, A.C.; Liu, T.; Schenker, M.; Yanez, P.; Tehfe, M.; Kowalyszyn, R.; Karamouzis, M.V.; Bruges, R.; Zander, T.; Pazo-Cid, R.; Hitre, E.; Feeney, K.; Cleary, J.M.; Poulart, V.; Cullen, D.; Lei, M.; Xiao, H.; Kondo, K.; Li, M.; Ajani, J.A. A plain language summary of the CheckMate 649 study: Nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus. Future Oncol., 2023, 19(11), 739-752. doi: 10.2217/fon-2022-1149 PMID: 36919706
  7. Janjigian, Y.Y.; Shitara, K.; Moehler, M.; Garrido, M.; Salman, P.; Shen, L.; Wyrwicz, L.; Yamaguchi, K.; Skoczylas, T.; Campos Bragagnoli, A.; Liu, T.; Schenker, M.; Yanez, P.; Tehfe, M.; Kowalyszyn, R.; Karamouzis, M.V.; Bruges, R.; Zander, T.; Pazo-Cid, R.; Hitre, E.; Feeney, K.; Cleary, J.M.; Poulart, V.; Cullen, D.; Lei, M.; Xiao, H.; Kondo, K.; Li, M.; Ajani, J.A. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet, 2021, 398(10294), 27-40. doi: 10.1016/S0140-6736(21)00797-2 PMID: 34102137
  8. Entezam, M.; Sanaei, M.J.; Mirzaei, Y.; Mer, A.H.; Abdollahpour-Alitappeh, M.; Azadegan-Dehkordi, F.; Bagheri, N. Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach. Life Sci., 2023, 318, 121459. doi: 10.1016/j.lfs.2023.121459 PMID: 36720453
  9. Wang, J.; Yuan, R.; Song, W.; Sun, J.; Liu, D.; Li, Z. PD-1, PD-L1 (B7-H1) and tumor-site immune modulation therapy: The historical perspective. J. Hematol. Oncol., 2017, 10(1), 34. doi: 10.1186/s13045-017-0403-5 PMID: 28122590
  10. Iwai, Y.; Ishida, M.; Tanaka, Y.; Okazaki, T.; Honjo, T.; Minato, N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci., 2002, 99(19), 12293-12297. doi: 10.1073/pnas.192461099 PMID: 12218188
  11. Xie, T.; Zhang, Z.; Zhang, X.; Qi, C.; Shen, L.; Peng, Z. Appropriate PD-L1 cutoff value for gastric cancer immunotherapy: A Systematic review and meta-analysis. Front. Oncol., 2021, 11, 646355. doi: 10.3389/fonc.2021.646355 PMID: 34540656
  12. Gu, L.; Chen, M.; Guo, D.; Zhu, H.; Zhang, W.; Pan, J.; Zhong, X.; Li, X.; Qian, H.; Wang, X. PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis. PLoS One, 2017, 12(8), e0182692. doi: 10.1371/journal.pone.0182692 PMID: 28796808
  13. Kim, J.W.; Nam, K.H.; Ahn, S.H.; Park, D.J.; Kim, H.H.; Kim, S.H.; Chang, H.; Lee, J.O.; Kim, Y.J.; Lee, H.S.; Kim, J.H.; Bang, S.M.; Lee, J.S.; Lee, K.W. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer, 2016, 19(1), 42-52. doi: 10.1007/s10120-014-0440-5 PMID: 25424150
  14. Rha, S.Y.; Ku, G.Y.; Kim, H.S.; Chung, H.C.; Amlashi, F.G.; Maru, D.M.; Fein, C.A.; Tang, L.H.; Zhou, W.; Wu, T.; Peter, S.A.; Kelsen, D.P.; Ajani, J.A. PD-L1 expression and overall survival in Asian and Western patients with gastric cancer. Future Oncol., 2022, 18(21), 2623-2634. doi: 10.2217/fon-2022-0103 PMID: 35616013
  15. Lian, J.; Zhang, G.; Zhang, Y.; Liu, H.; Zhang, J.; Nan, P.; Tian, W. PD-L1 and HER2 expression in gastric adenocarcinoma and their prognostic significance. Dig. Liver Dis., 2022, 54(10), 1419-1427. doi: 10.1016/j.dld.2022.01.128 PMID: 35123909
  16. Ngoc Dung, T.; Mai Hanh, N.; Thai Tra, D.; Dinh Tien, T.; Thuy Linh, N.; Khac Tuyen, N.; Van Thinh, P.; Nhu Binh, D.; Manh Hung, N.; Thanh Chung, D. The relationship between PD-L1 expression and clinicopathological characteristics and prognosis of Vietnamese gastric cancer patients. Biomed. Res. Ther., 2022, 9(7), 5130-5139. doi: 10.15419/bmrat.v9i7.748
  17. Dislich, B.; Mertz, K.D.; Gloor, B.; Langer, R. Interspatial distribution of tumor and immune cells in correlation with PD-L1 in molecular subtypes of gastric cancers. Cancers, 2022, 14(7), 1736. doi: 10.3390/cancers14071736 PMID: 35406506
  18. Chen, X.; Zhang, H.; Wang, M.; Liu, H.; Hu, Y.; Lin, T.; Chen, H.; Zhao, M.; Chen, T.; Li, G.; Yu, J.; Zhao, L. Relationship between programmed death ligand 1 expression and other clinicopathological features in a large cohort of gastric cancer patients. Front. Immunol., 2022, 13, 783695. doi: 10.3389/fimmu.2022.783695 PMID: 35401534
  19. Che, H.; Xiong, Q.; Ma, J.; Chen, S.; Wu, H.; Xu, H.; Hou, B. Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors. BMC Cancer, 2022, 22(1), 904. doi: 10.1186/s12885-022-10004-9 PMID: 35986342
  20. Busuioc, C.I.; Birla, R.D.; Mitrea, M.; Ardeleanu, C.; Panaitescu, E.; Enache, S.; Iosif, C. PD-L1 expression in esophageal and gastroesophageal junction carcinoma, correlation with the immune infiltrate - Preliminary study. Chirurgia, 2022, 117(2), 204-210. doi: 10.21614/chirurgia.2738 PMID: 35535782
  21. Attia, S.; Abd El Hafez, A.; Abdel-Aziz, A.; Elmetwaly, S.; Mokhtar, N. Prognostic Value of PD-L1 immunohistochemical marker in gastric carcinoma and its correlation with HER2 status. Asian Pac. J. Cancer Prev., 2022, 23(4), 1433-1444. doi: 10.31557/APJCP.2022.23.4.1433 PMID: 35485706
  22. Amirmoezi, F.; Geramizadeh, B. Molecular classification of gastric cancer with emphasis on PDL-1 expression: The first report from Iran. Clin. Pathol., 2022, 15, 2632010X2210963. doi: 10.1177/2632010X221096378 PMID: 35651850
  23. Zhang, C.; Zhao, S.; Wang, X. Co-expression of CMTM6 and PD-L1: A novel prognostic indicator of gastric cancer. Cancer Cell Int., 2021, 21(1), 78. doi: 10.1186/s12935-020-01734-6 PMID: 33509216
  24. Yamashita, S.; Abe, H.; Kunita, A.; Yamashita, H.; Seto, Y.; Ushiku, T. Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma. Histopathology, 2021, 78(3), 381-391. doi: 10.1111/his.14230 PMID: 32767778
  25. Ubukata, Y.; Ogata, K.; Sohda, M.; Yokobori, T.; Shimoda, Y.; Handa, T.; Nakazawa, N.; Kimura, A.; Kogure, N.; Sano, A.; Sakai, M.; Ogawa, H.; Kuwano, H.; Shirabe, K.; Oyama, T.; Saeki, H. Role of PD-L1 expression during the progression of submucosal gastric cancer. Oncology, 2021, 99(1), 15-22. doi: 10.1159/000509033 PMID: 33113541
  26. Shi, L.; Wu, Z.; Song, H.; Xu, W.; Xu, Y.; Yang, L.; Song, J.; Guan, W. Intralymph node expressions of A2AR and PD-L1 were associated with metastasis and a poor prognosis in gastric cancer. Indian J. Surg., 2021, 83(2), 505-512. doi: 10.1007/s12262-020-02396-4
  27. Shekarriz, R.; Hedayatizadeh-Omran, A.; Amjadi, O.; Alizadeh-Navaei, R.; Godazandeh, G. Serum level of programmed death-ligand 1 in patients with gastric cancer in mazandaran province as a high-risk region in Iran. Clin. Cancer Investig. J., 2021, 10(1), 5-10. doi: 10.4103/ccij.ccij_128_20
  28. Saurabh, A.; Raphael, V.; Dey, B.; Harris, C.; Jagtap, V.; Das, U. Expression of PDL1 and Her2neu in gastric and gastroesophageal junction adenocarcinoma. Indian J. Surg. Oncol., 2021, 12(S1), 144-151. doi: 10.1007/s13193-020-01245-w PMID: 33994740
  29. Pereira, M.A.; Ramos, M.; Dias, A.R.; Ribeiro, R.; Cardili, L.; Zilberstein, B.; Cecconello, I.; Ribeiro, U., Jr; de Mello, E.S.; de Castria, T.B. Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer. Virchows Archiv : Int. J. Pathol., 2021, 478(6), 1039-1048. doi: 10.1007/s00428-020-02956-9 PMID: 33098489
  30. Mimura, K.; Kua, L.F.; Xiao, J.F.; Asuncion, B.R.; Nakayama, Y.; Syn, N.; Fazreen, Z.; Soong, R.; Kono, K.; Yong, W.P. Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer–T cell coculture models. Gastric Cancer, 2021, 24(3), 611-623. doi: 10.1007/s10120-020-01151-8 PMID: 33611641
  31. Lv, H.; Zhang, J.; Sun, K.; Nie, C.; Chen, B.; Wang, J.; Xu, W.; Wang, S.; Liu, Y.; Chen, X. Expression of human epidermal growth factor receptor-2 status and programmed cell death protein-1 ligand is associated with prognosis in gastric cancer. Front. Oncol., 2021, 10, 580045. doi: 10.3389/fonc.2020.580045
  32. Li, X.; Zhang, L.; Wang, C.; Huang, J.; Zhu, J.; Huang, Y.; Chen, Y.; Jia, J.; Jiang, G. Microsatellite instability in Chinese gastric cancer and its correlation with clinical characteristics. J. Gastrointest. Oncol., 2021, 12(6), 2719-2727. doi: 10.21037/jgo-21-695 PMID: 35070401
  33. Bahsi, S.; Yildiz, I.; Erdamar, S.; Goksel, S.; Tozun, N.; Aytac, E.; Demir, G.; Er, O.; Baca, B.; Karahasanoglu, T.; Hamzaoglu, I.; Ozer, L.; Bozkurt, M.; Uras, C.; Bayoglu, I.V.; Dulgeroglu, O.; Ince, U. Clinicopathological and prognostic significance of msi status and pd-l1 expression in turkish patients with gastric cancer. UHOD Uluslar. Hematol. Onkol. Derg., 2021, 31(4), 246-254.
  34. Zhou, K.I.; Peterson, B.; Serritella, A.; Thomas, J.; Reizine, N.; Moya, S.; Tan, C.; Wang, Y.; Catenacci, D.V.T. Spatial and temporal heterogeneity of pd-l1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy. Clin. Cancer Res., 2020, 26(24), 6453-6463. doi: 10.1158/1078-0432.CCR-20-2085 PMID: 32820017
  35. Yun, T.; Wang, S.; Jiang, B.; Wang, C.; Meng, N.; Yuan, X.; Wang, Y. Significance of detection of the HER2 Gene and PD-1/PD-L1 in gastric cancer. J Oncol., 2020, 2020, 8678945. doi: 10.1155/2020/8678945 PMID: 33123197
  36. Yamashita, K.; Iwatsuki, M.; Harada, K.; Eto, K.; Hiyoshi, Y.; Ishimoto, T.; Nagai, Y.; Iwagami, S.; Miyamoto, Y.; Yoshida, N.; Komohara, Y.; Ajani, J.A.; Baba, H. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer. Gastric Cancer, 2020, 23(1), 95-104. doi: 10.1007/s10120-019-00999-9 PMID: 31451991
  37. Wang, Y.; Wang, S.; Zhu, C.; Cao, H.; Zhang, Z.; Zhao, E. The association between immune characteristic and clinical pathology in Chinese patients with adenocarcinoma of esophagogastric junction. Cancer Manag. Res., 2020, 12, 3259-3269. doi: 10.2147/CMAR.S235722 PMID: 32494190
  38. Wang, X.Y.; Hu, Y.J.; Dong, K.; Zhao, C.; Huang, X.Z.; Lian, S.Y.; Sun, Y. Expression level and prognostic value of PD-L1 in microsatellite instability-high gastric cancer. Chinese J. Pathol., 2020, 49(11), 1114-1119. doi: 10.3760/cma.j.cn112151-20200323-00245 PMID: 33152814
  39. Wang, J.; Shang, S.; Li, J.; Deng, H.; Ouyang, L.; Xie, H.; Zhu, H.; Li, Y.; Zuo, C. PD-L1 and MiR-34a are prognostic factors for primary gastric diffuse large B-cell lymphoma patients treated with R-CHOP. Cancer Manag. Res., 2020, 12, 4999-5008. doi: 10.2147/CMAR.S247874 PMID: 32612387
  40. Sughayer, M.A.; Dabbagh, T.Z.; Battah, A.H. PD-L1 expression is a favorable prognostic marker in gastric carcinoma. Appl. Immunohistochem. Mol. Morphol., 2020, 28(10), 748-754. doi: 10.1097/PAI.0000000000000834 PMID: 32205740
  41. Pötzsch, M.; Berg, E.; Hummel, M.; Stein, U.; von Winterfeld, M.; Jöhrens, K.; Rau, B.; Daum, S.; Treese, C. Better prognosis of gastric cancer patients with high levels of tumor infiltrating lymphocytes is counteracted by PD-1 expression. OncoImmunology, 2020, 9(1), 1824632. doi: 10.1080/2162402X.2020.1824632 PMID: 33101772
  42. Liu, X.; Choi, M.G.; Kim, K.; Kim, K.M.; Kim, S.T.; Park, S.H.; Cristescu, R.; Peter, S.; Lee, J. High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features. Pathol. Res. Pract., 2020, 216(4), 152881. doi: 10.1016/j.prp.2020.152881 PMID: 32089413
  43. Lian, J.; Nan, P.; Zhang, G.; Zhang, Y. Correlation between expression of PD-L1 and HER-2 in gastric adenocarcinoma and its prognostic significance. Chinese J. Clin. Experimen. Pathol., 2020, 36(6), 636-641.
  44. Ito, S.; Masuda, T.; Noda, M.; Hu, Q.; Shimizu, D.; Kuroda, Y.; Eguchi, H.; Tobo, T.; Utsunomiya, T.; Mimori, K. Prognostic significance of PD-1, PD-L1 and CD8 gene expression levels in gastric cancer. Oncology, 2020, 98(7), 501-511. doi: 10.1159/000506075 PMID: 32380498
  45. Kim, D.H.; Bae, G.E.; Suh, K.S.; Ryuman, D.; Song, K.S.; Kim, J.S.; Lee, S.; Yeo, M.K. Clinical significance of tumor and immune cell PD-L1 expression in gastric adenocarcinoma. In Vivo, 2020, 34(6), 3171-3180. doi: 10.21873/invivo.12152 PMID: 33144421
  46. Choi, E.; Chang, M.S.; Byeon, S.; Jin, H.; Jung, K.C.; Kim, H.; Lee, K.L.; Kim, W.; Park, J.H.; Kim, K.H.; Kim, J.S.; Choi, I.S.; Han, D.S.; Ahn, H.S.; Heo, S.C. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas. Diagn. Pathol., 2020, 15(1), 69. doi: 10.1186/s13000-020-00979-z PMID: 32498695
  47. Yang, M.W.; Fu, X.L.; Jiang, Y.S.; Chen, X.J.; Tao, L.Y.; Yang, J.Y.; Huo, Y.M.; Liu, W.; Zhang, J.F.; Liu, P.F.; Liu, Q.; Hua, R.; Zhang, Z.G.; Sun, Y.W.; Liu, D.J. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas. World J. Gastroenterol., 2019, 25(14), 1684-1696. doi: 10.3748/wjg.v25.i14.1684 PMID: 31011254
  48. Won, K.Y.; Kim, G.Y.; Kim, H.K.; Song, M.J.; Choi, S.I.; Bae, G.E.; Lim, S.J. The expression of C-MYC in gastric adenocarcinoma is associated with PD-L1 and FOXP3 expression: C-MYC overexpression is a good prognostic factor. Pathol. Res. Pract., 2019, 215(11), 152639. doi: 10.1016/j.prp.2019.152639 PMID: 31582185
  49. Wang, C.; Yu, J.; Fan, Y.; Ma, K.; Ning, J.; Hu, Y.; Niu, W.; Dong, X.; Wu, Y.; Li, E.; Dong, D. The clinical significance of PD-L1/PD-1 expression in gastroenteropancreatic neuroendocrine neoplasia. Ann. Clin. Lab. Sci., 2019, 49(4), 448-456. PMID: 31471333
  50. Svensson, M.C.; Borg, D.; Zhang, C.; Hedner, C.; Nodin, B.; Uhlén, M.; Mardinoglu, A.; Leandersson, K.; Jirström, K. Expression of PD-L1 and PD-1 in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma: Relationship with mismatch repair status and survival. Front. Oncol., 2019, 9, 136. doi: 10.3389/fonc.2019.00136 PMID: 30931254
  51. Sun, Y.; Yu, W.; Guan, W.; cai, L.; Qiao, M.; Zheng, L.; Jiang, R.; Wang, R.; Wang, L. Integrated assessment of PD-L1 expression and molecular classification facilitates therapy selection and prognosis prediction in gastric cancer. Cancer Manag. Res., 2019, 11, 6397-6410. doi: 10.2147/CMAR.S206189 PMID: 31372044
  52. Mu, L.; Yu, W.; Su, H.; Lin, Y.; Sui, W.; Yu, X.; Qin, C. Relationship between the expressions of PD-L1 and tumour-associated fibroblasts in gastric cancer. Artif. Cells Nanomed. Biotechnol., 2019, 47(1), 1036-1042. doi: 10.1080/21691401.2019.1573741 PMID: 30983436
  53. Morihiro, T.; Kuroda, S.; Kanaya, N.; Kakiuchi, Y.; Kubota, T.; Aoyama, K.; Tanaka, T.; Kikuchi, S.; Nagasaka, T.; Nishizaki, M.; Kagawa, S.; Tazawa, H.; Fujiwara, T. PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer. Sci. Rep., 2019, 9(1), 4633. doi: 10.1038/s41598-019-41177-2 PMID: 30874607
  54. Knief, J.; Lazar-Karsten, P.; Hummel, R.; Wellner, U.; Thorns, C. PD-L1 expression in carcinoma of the esophagogastric junction is positively correlated with T-cell infiltration and overall survival. Pathol. Res. Pract., 2019, 215(6), 152402. doi: 10.1016/j.prp.2019.03.030 PMID: 31043352
  55. Kim, J.Y.; Kim, W.G.; Kwon, C.H.; Park, D.Y. Differences in immune contextures among different molecular subtypes of gastric cancer and their prognostic impact. Gastric Cancer, 2019, 22(6), 1164-1175. doi: 10.1007/s10120-019-00974-4 PMID: 31152268
  56. Kim, J.H.; Kim, S.Y.; Shin, E.Y.; Jung, J.H.; Choi, H.J.; Jun, K.H. Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer. Oncol. Lett., 2019, 18(3), 2661-2669. doi: 10.3892/ol.2019.10594 PMID: 31452748 PMID: 31452748
  57. Kawazoe, A.; Shitara, K.; Kuboki, Y.; Bando, H.; Kojima, T.; Yoshino, T.; Ohtsu, A.; Ochiai, A.; Togashi, Y.; Nishikawa, H.; Doi, T.; Kuwata, T. Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein–Barr virus status, and cancer genome alterations in metastatic gastric cancer. Gastric Cancer, 2019, 22(1), 69-76. doi: 10.1007/s10120-018-0843-9 PMID: 29859006
  58. Hashimoto, T.; Kurokawa, Y.; Takahashi, T.; Miyazaki, Y.; Tanaka, K.; Makino, T.; Yamasaki, M.; Nakajima, K.; Ikeda, J.; Mori, M.; Doki, Y. Predictive value of MLH1 and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer. Gastric Cancer, 2019, 22(4), 785-792. doi: 10.1007/s10120-018-00918-4 PMID: 30617648
  59. Zhang, F.; Qiao, J.; Wang, Y.; Zhao, F.; Zhang, S.; Zhang, R. Expression and clinical significance of PD-1 /PD-L1 in gastric cancer tissues. Zhongguo Zhongliu Shengwu Zhiliao Zazhi, 2018, 25(2), 170-176.
  60. Zhang, C.; Li, Z.; Xu, L.; Che, X.; Wen, T.; Fan, Y.; Li, C.; Wang, S.; Cheng, Y.; Wang, X.; Qu, X.; Liu, Y. CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer. BMC Cancer, 2018, 18(1), 462. doi: 10.1186/s12885-018-4384-8 PMID: 29690901
  61. Xing, X.; Guo, J.; Ding, G.; Li, B.; Dong, B.; Feng, Q.; Li, S.; Zhang, J.; Ying, X.; Cheng, X.; Guo, T.; Du, H.; Hu, Y.; Zhou, T.; Wang, X.; Li, L.; Li, Q.; Xie, M.; Li, L.; Gao, X.; Shan, F.; Li, Z.; Jia, S.; Wen, X.; Wang, J.; Ji, J. Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. OncoImmunology, 2018, 7(3), e1356144. doi: 10.1080/2162402X.2017.1356144 PMID: 29399387
  62. Wei, W.; Zhang, D.; Xu, B.; Jiang, J.; Wu, C. Upregulation of programmed death ligand 1 and epidermal growth factor receptor is associated with poor prognosis in gastric cancer. Transl. Cancer Res., 2018, 7(2), 330-340. doi: 10.21037/tcr.2018.03.15
  63. Sundar, R.; Qamra, A.; Tan, A.L.K.; Zhang, S.; Ng, C.C.Y.; Teh, B.T.; Lee, J.; Kim, K.M.; Tan, P. Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes. Gastric Cancer, 2018, 21(6), 1064-1070. doi: 10.1007/s10120-018-0851-9 PMID: 29915957
  64. Saito, H.; Kono, Y.; Murakami, Y.; Shishido, Y.; Kuroda, H.; Matsunaga, T.; Fukumoto, Y.; Osaki, T.; Ashida, K.; Fujiwara, Y. Highly activated PD-1/PD-L1 pathway in gastric cancer with PD-L1 expression. Anticancer Res., 2018, 38(1), 107-112. doi: 10.21873/anticanres.12197 PMID: 29277762
  65. Pereira, M.A.; Ramos, M.F.K.P.; Faraj, S.F.; Dias, A.R.; Yagi, O.K.; Zilberstein, B.; Cecconello, I.; Alves, V.A.F.; de Mello, E.S.; Ribeiro, U., Jr Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer. J. Surg. Oncol., 2018, 117(5), 829-839. doi: 10.1002/jso.25022 PMID: 29534305
  66. Noh, B.J.; Kim, J.H.; Eom, D.W. Prognostic significance of categorizing gastric carcinoma by PD-L1 expression and tumor infiltrating lymphocytes. Ann. Clin. Lab. Sci., 2018, 48(6), 695-706. PMID: 30610038
  67. Liu, Y.; Wang, J.F.; Li, X.W.; Bu, P.; Bai, W.; Li, L.M. Relationship between PD-L1 protein expression and gene amplification in gastric cancer tissues. Chinese J. Pathol., 2018, 47(8), 597-602. doi: 10.3760/cma.j.issn.0529-5807.2018.08.006 PMID: 30107664
  68. Li, Y.; Bao, F.; Xiang, Y.; Dai, Y.; He, J.; Ma, C.; Zhang, Z. Expression of PD1 /PD-L1 in gastric carcinoma and its correlation with clinicopathological characteristics and prognosis. Chinese J. Clin. Experimen. Pathol., 2018, 34(6), 614-618.
  69. Harada, K.; Dong, X.; Estrella, J.S.; Correa, A.M.; Xu, Y.; Hofstetter, W.L.; Sudo, K.; Onodera, H.; Suzuki, K.; Suzuki, A.; Johnson, R.L.; Wang, Z.; Song, S.; Ajani, J.A. Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. Gastric Cancer, 2018, 21(1), 31-40. doi: 10.1007/s10120-017-0760-3 PMID: 28801853
  70. Gao, Y.; Li, S.; Xu, D.; Chen, S.; Cai, Y.; Jiang, W.; Zhang, X.; Sun, J.; Wang, K.; Chang, B.; Wang, F.; Hong, M. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma. Chin. J. Cancer, 2017, 36(1), 61. doi: 10.1186/s40880-017-0226-3 PMID: 28754154
  71. Wu, Y.; Cao, D.; Qu, L.; Cao, X.; Jia, Z.; Zhao, T.; Wang, Q.; Jiang, J. PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer. Oncotarget, 2017, 8(38), 64066-64082. doi: 10.18632/oncotarget.19318 PMID: 28969052
  72. Thompson, E.D.; Zahurak, M.; Murphy, A.; Cornish, T.; Cuka, N.; Abdelfatah, E.; Yang, S.; Duncan, M.; Ahuja, N.; Taube, J.M.; Anders, R.A.; Kelly, R.J. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut, 2017, 66(5), 794-801. doi: 10.1136/gutjnl-2015-310839 PMID: 26801886
  73. Seo, A.N.; Kang, B.W.; Kwon, O.K.; Park, K.B.; Lee, S.S.; Chung, H.Y.; Yu, W.; Bae, H.I.; Jeon, S.W.; Kang, H.; Kim, J.G. Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein–Barr virus-associated gastric cancer. Br. J. Cancer, 2017, 117(12), 1753-1760. doi: 10.1038/bjc.2017.369 PMID: 29073638
  74. Oki, E.; Okano, S.; Saeki, H.; Umemoto, Y.; Teraishi, K.; Nakaji, Y.; Ando, K.; Zaitsu, Y.; Yamashita, N.; Sugiyama, M.; Nakashima, Y.; Ohgaki, K.; Oda, Y.; Maehara, Y. Protein expression of programmed death 1 Ligand 1 and HER2 in gastric carcinoma. Oncology, 2017, 93(6), 387-394. doi: 10.1159/000479231 PMID: 28910818
  75. Kwon, M.J.; Kim, K.C.; Nam, E.S.; Cho, S.J.; Park, H.R.; Min, S.K.; Seo, J.; Choe, J.Y.; Lee, H.K.; Kang, H.S.; Min, K.W. Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection. Oncotarget, 2017, 8(47), 82399-82414. doi: 10.18632/oncotarget.19390 PMID: 29137273
  76. Kim, K.J.; Yang, H.K.; Kim, W.H.; Kang, G.H. Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers. Oncotarget, 2017, 8(35), 58887-58902. doi: 10.18632/oncotarget.19439 PMID: 28938605
  77. Kawazoe, A.; Kuwata, T.; Kuboki, Y.; Shitara, K.; Nagatsuma, A.K.; Aizawa, M.; Yoshino, T.; Doi, T.; Ohtsu, A.; Ochiai, A. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. Gastric Cancer, 2017, 20(3), 407-415. doi: 10.1007/s10120-016-0631-3 PMID: 27629881
  78. Ju, X.; Shen, R.; Huang, P.; Zhai, J.; Qian, X.; Wang, Q.; Chen, M. Predictive relevance of PD-L1 expression with pre-existing TILs in gastric cancer. Oncotarget, 2017, 8(59), 99372-99381. doi: 10.18632/oncotarget.22079 PMID: 29245908
  79. Hsu, J.T.; Hsu, C.S.; Le, P.H.; Chen, T.C.; Chou, W.C.; Lin, C.Y.; Yeh, T.S. Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1. J. Surg. Res., 2017, 211, 30-38. doi: 10.1016/j.jss.2016.11.058 PMID: 28501128
  80. Fang, W.; Chen, Y.; Sheng, J.; Zhou, T.; Zhang, Y.; Zhan, J.; Liu, L.; Huang, J.; Peng, P.; Zhang, L. Association between PD-L1 expression on tumour-infiltrating lymphocytes and overall survival in patients with gastric cancer. J. Cancer, 2017, 8(9), 1579-1585. doi: 10.7150/jca.18729 PMID: 28775777
  81. Ma, C.; Patel, K.; Singhi, A.D.; Ren, B.; Zhu, B.; Shaikh, F.; Sun, W. Programmed death-ligand 1 expression is common in gastric cancer associated with epstein-barr virus or microsatellite instability. Am. J. Surg. Pathol., 2016, 40(11), 1496-1506. doi: 10.1097/PAS.0000000000000698 PMID: 27465786
  82. Li, Z.; Lai, Y.; Sun, L.; Zhang, X.; Liu, R.; Feng, G.; Zhou, L.; Jia, L.; Huang, X.; Kang, Q.; Lin, D.; Gao, J.; Shen, L. PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. Hum. Pathol., 2016, 55, 182-189. doi: 10.1016/j.humpath.2016.05.012 PMID: 27260946
  83. Eto, S.; Yoshikawa, K.; Nishi, M.; Higashijima, J.; Tokunaga, T.; Nakao, T.; Kashihara, H.; Takasu, C.; Iwata, T.; Shimada, M. Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection. Gastric Cancer, 2016, 19(2), 466-471. doi: 10.1007/s10120-015-0519-7 PMID: 26210691
  84. Dong, M.; Wang, H.; Zhao, X.; Chen, J.; Zhang, Y.; Huang, Y.; Xue, L.; Li, H.; Du, H.; Wu, X.; Shao, C. Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in epstein-barr virus–associated gastric carcinoma. Hum. Pathol., 2016, 53, 25-34. doi: 10.1016/j.humpath.2016.02.007 PMID: 26980034
  85. Dai, C.; Geng, R.; Wang, C.; Wong, A.; Qing, M.; Hu, J.; Sun, Y.; Lo, A.W.I.; Li, J. Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer. Mol. Oncol., 2016, 10(10), 1551-1558. doi: 10.1016/j.molonc.2016.09.004 PMID: 27720576
  86. Chang, H.; Jung, W.Y.; Kang, Y.; Lee, H.; Kim, A.; Kim, H.K.; Shin, B.K.; Kim, B. Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group. Oncotarget, 2016, 7(49), 80426-80434. doi: 10.18632/oncotarget.12603 PMID: 27741514
  87. Böger, C.; Behrens, H.M.; Mathiak, M.; Krüger, S.; Kalthoff, H.; Röcken, C. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget, 2016, 7(17), 24269-24283. doi: 10.18632/oncotarget.8169 PMID: 27009855
  88. Zhang, L.; Qiu, M.; Jin, Y.; Ji, J.; Li, B.; Wang, X.; Yan, S.; Xu, R.; Yang, D. Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. Int. J. Clin. Exp. Pathol., 2015, 8(9), 11084-11091. PMID: 26617827
  89. Qing, Y.; Li, Q.; Ren, T.; Xia, W.; Peng, Y.; Liu, G.; Luo, H.; Yang, Y.; Dai, X.; Zhou, S.F.; Wang, D. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des. Devel. Ther., 2015, 9, 901-909. doi: 10.2147/DDDT.S75152 PMID: 25733810
  90. Geng, Y.; Wang, H.; Lu, C.; Li, Q.; Xu, B.; Jiang, J.; Wu, C. Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance. Int. J. Clin. Oncol., 2015, 20(2), 273-281. doi: 10.1007/s10147-014-0701-7 PMID: 24804867
  91. Lu, C.; Li, Q.; Wang, H.; Geng, Y.; Tian, B.; Xie, J.; Tan, Y.; Wu, C. Expression and clinical significance of costimulatory molecules B7-H1, B7-H4 and forkhead box P3~+ regulatory T cells in gastric carcinoma. Chin. J. Exp. Surg., 2014, 31(3), 492-494.
  92. Jiang, D.; Xu, Y.; Li, F.; Xu, B.; Zhang, X. The role of B7-H1 in gastric carcinoma: Clinical significance and related mechanism. Med. Oncol., 2014, 31(11), 268. doi: 10.1007/s12032-014-0268-1 PMID: 25311064
  93. Hou, J.; Yu, Z.; Xiang, R.; Li, C.; Wang, L.; Chen, S.; Li, Q.; Chen, M.; Wang, L. Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer. Exp. Mol. Pathol., 2014, 96(3), 284-291. doi: 10.1016/j.yexmp.2014.03.005 PMID: 24657498
  94. Liu, S.M.; Meng, Q.; Zhang, Q.X.; Wang, S.D.; Liu, Z.J.; Zhang, X.F. Expression and significance of B7-H1 and its receptor PD-1 in human gastric carcinoma. Zhonghua Zhong Liu Za Zhi, 2008, 30(3), 192-195. PMID: 18756934
  95. Sun, J.; Xu, K.; Wu, C.; Wang, Y.; Hu, Y.; Zhu, Y.; Chen, Y.; Shi, Q.; Yu, G.; Zhang, X. PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies. Tissue Antigens, 2007, 69(1), 19-27. doi: 10.1111/j.1399-0039.2006.00701.x PMID: 17212704
  96. Wu, C.; Zhu, Y.; Jiang, J.; Zhao, J.; Zhang, X.G.; Xu, N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem., 2006, 108(1), 19-24. doi: 10.1016/j.acthis.2006.01.003 PMID: 16530813
  97. Wang, L.; Zhang, Q.; Ni, S.; Tan, C.; Cai, X.; Huang, D.; Sheng, W. Programmed death-ligand 1 expression in gastric cancer: Correlation with mismatch repair deficiency and HER2-negative status. Cancer Med., 2018, 7(6), 2612-2620. doi: 10.1002/cam4.1502 PMID: 29673110
  98. Lima, Á.; Sousa, H.; Medeiros, R.; Nobre, A.; Machado, M. PD-L1 expression in EBV associated gastric cancer: A systematic review and meta-analysis. Discover Oncology, 2022, 13(1), 19. doi: 10.1007/s12672-022-00479-0 PMID: 35318527
  99. Murphy, G.; Pfeiffer, R.; Camargo, M.C.; Rabkin, C.S. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology, 2009, 137(3), 824-833. doi: 10.1053/j.gastro.2009.05.001 PMID: 19445939
  100. Li, X.; Zhang, W. Expression of PD-L1 in EBV-associated malignancies. Int. Immunopharmacol., 2021, 95, 107553. doi: 10.1016/j.intimp.2021.107553 PMID: 33765613
  101. Angerilli, V.; Parente, P.; Campora, M.; Ugolini, C.; Battista, S.; Cassoni, P.; Gambella, A.; Cavallin, F.; De Lisi, G.; Vanoli, A.; Grillo, F.; Mastracci, L.; Fassan, M. HER2-low in gastro-oesophageal adenocarcinoma: A real-world pathological perspective. J. Clin. Pathol., 2023, 208767. doi: 10.1136/jcp-2023-208767 PMID: 37055161
  102. Dai, X.; Bu, X.; Gao, Y.; Guo, J.; Hu, J.; Jiang, C.; Zhang, Z.; Xu, K.; Duan, J.; He, S.; Zhang, J.; Wan, L.; Liu, T.; Zhou, X.; Hung, M.C.; Freeman, G.J.; Wei, W. Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. Mol. Cell, 2021, 81(11), 2317-2331.e6. doi: 10.1016/j.molcel.2021.03.037 PMID: 33909988
  103. Li, Z.; Zhang, C.; Du, J.X.; Zhao, J.; Shi, M.T.; Jin, M.W.; Liu, H. Adipocytes promote tumor progression and induce PD-L1 expression via TNF-α/IL-6 signaling. Cancer Cell Int., 2020, 20(1), 179. doi: 10.1186/s12935-020-01269-w PMID: 32477009
  104. Szczyrek, M.; Bitkowska, P.; Chunowski, P.; Czuchryta, P.; Krawczyk, P.; Milanowski, J. Diet, microbiome, and cancer immunotherapy-A comprehensive review. Nutrients, 2021, 13(7), 2217. doi: 10.3390/nu13072217 PMID: 34203292
  105. Handford, J.; Chen, M.; Rai, R.; Moss, C.L.; Enting, D.; Peat, N.; Karagiannis, S.N.; Van Hemelrijck, M.; Russell, B. Is there a role for exercise when treating patients with cancer with immune checkpoint inhibitors? A scoping review. Cancers, 2022, 14(20), 5039. doi: 10.3390/cancers14205039 PMID: 36291823
  106. Zhao, Y.; Jia, Y.; Shi, T.; Wang, W.; Shao, D.; Zheng, X.; Sun, M.; He, K.; Chen, L. Depression promotes hepatocellular carcinoma progression through a glucocorticoid-mediated upregulation of PD-1 expression in tumor-infiltrating NK cells. Carcinogenesis, 2019. doi: 10.1093/carcin/bgz017 PMID: 30715244
  107. Huang, K.W.; Huang, T.L. Association between programmed death-1 pathway and major depression. World J. Biol. Psychiatry, 2023, 1-7. doi: 10.1080/15622975.2023.2209876 PMID: 37139744
  108. Dickinson, S.E.; Khawam, M.; Kirschnerova, V.; Vaishampayan, P.; Centuori, S.M.; Saboda, K.; Calvert, V.S.; Petricoin, E.F., III; Curiel-Lewandrowski, C. Increased PD-L1 expression in human skin acutely and chronically exposed to UV irradiation. Photochem. Photobiol., 2021, 97(4), 778-784. doi: 10.1111/php.13406 PMID: 33615483
  109. Zhang, M.; Dong, Y.; Liu, H.; Wang, Y.; Zhao, S.; Xuan, Q.; Wang, Y.; Zhang, Q. The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: A meta-analysis of 10 studies with 1,901 patients. Sci. Rep., 2016, 6(1), 37933. doi: 10.1038/srep37933 PMID: 27892511
  110. Ren, J.; He, Q.; Yin, H.; Zheng, L.; Li, L.; Wu, X. Prognostic role and clinical significance of tumor-infiltrating lymphocyte (TIL) and programmed death ligand 1 (PD-L1) expression in gastric cancer: A systematic review and meta-analysis. Clin. Transl. Oncol., 2023, 25(5), 1436-1445. doi: 10.1007/s12094-022-03040-1 PMID: 36528835

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers